Early Korean COVID Cohort Did Not Find a Significant Benzodiazepine Mortality Association

A population-based historical analysis found different results across medication groups, including a nonsignificant benzodiazepine comparison.

What the source reports

The study included 7,713 adults with COVID-19 in South Korean insurance data. It examined musculoskeletal diagnoses and several medication categories in relation to in-hospital mortality. Benzodiazepine exposure was not significantly associated with mortality in the adjusted analysis, unlike the reported strong-opioid signal.

Limits and uncertainty

Absence of statistical significance is not proof of no effect or universal safety. Claims-based conditions may be misclassified, and important variables such as body mass index, smoking, and alcohol history were unavailable. The early-pandemic setting limits application to other periods and clinical populations.

Implications for forensic review

An expert should report the benzodiazepine result on its own terms rather than importing another drug group’s association. This study neither proves that benzodiazepines caused COVID deaths nor guarantees harmlessness. Individual respiratory and mortality opinions still require exposure timing, clinical severity, and competing explanations.

Source and related reading

Source reviewed: Musculoskeletal Disorders Pain Medication and in Hospital Mortality among Patients with COVID 19 in (PMC8295800). Forensic applications above are interpretive analysis of the supplied paper.

Related reading: A Palliative-Care Cohort Did Not Detect a Benzodiazepine–Delirium Association; Five-Year Mortality Association Cannot Serve as an Acute Benzodiazepine Lethality Estimate.